In Europe, there are more than 100 blood glucose (BG) systems on the market. There is also fierce competition between a number of large companies (the "big four") and numerous smaller companies (>30). Although the market for self-monitoring of blood glucose (SMBG) still sees a constant increase in sales each and every year (but with steady declines in growth), the countermeasures by health insurance companies to reduce the cost burden/expenses for SMBG have started to bring down the margin of these companies.
In Europe, there are more than 100 blood glucose (BG) systems on the market. There is also fierce competition between a number of large companies (the "big four") and numerous smaller companies (>30). Although the market for self-monitoring of blood glucose (SMBG) still sees a constant increase in sales each and every year (but with steady declines in growth), the countermeasures by health insurance companies to reduce the cost burden/expenses for SMBG have started to bring down the margin of these companies. 1 An important marketing argument is the accuracy of the BG systems. We have recently seen a number of publications of mostly company-sponsored studies about this topic, after a period of many years where little was wrtitten about the tremendous importance of accuracy. It is not the aim of this editorial to discuss the appropriate performance of such accuracy studies, which are impressively complex to perform as outlined by Thorpe, 2 but to highlight a critical move recently made by a company in Europe.
Two excellent articles 3,4 by Freckmann and coauthors have been published in this journal, one about batch-to-batch differences in measurement performance (another widely ignored topic) and one in which his scientific institute evaluated the system accuracy of a number of BG systems with respect to their fulfillment of the system accuracy criteria indicated by the International Organization for Standardization (ISO 15197:2003) . 5 The good news is, only ~20% of the systems tested do not fulfill the requirements of the ISO standard; however, the bad news is, ~47% do not fulfill the stricter requirements of the revised ISO standard, 6 which has been published this year. However, in Europe, companies have until December 2016 for their systems to fulfill the requirements of the revised standard.
Earlier this year, Freckmann's published study for system accuracy evaluation of BG monitoring systems 3 was attacked judicially by a European manufacturer and his resellers in various European countries because they do not agree with the results regarding their products tested in the study. They wanted to force Freckmann and the Institut für DiabetesTechnologie Forschungs-und Entwicklungsgesellschaft mbH an der Universität Ulm (IDT) to withdraw the results of the evaluated system and to stop citing the published results of the study. They tried to prevail upon Freckmann and the IDT to publish a counterstatement that declares that the performance of the study was not adequate to show compliance with the system accuracy criteria of ISO 15197:2003, at least for their system. It must be acknowledged that not all statements in the ISO standard are precise; they contain some ambiguity. In this study, only one batch was evaluated (the revised ISO standard asks for three batches), and it might have been an unfortunate coincidence for this company that a bad batch of their strips was tested. However, all materials used in this study were reported to have been purchased on the market. Now, if you start thinking about this for a second, it leads to the question, How good is the internal quality control of this company that they have released this batch
